NCT07904754
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 1 with changes below, 1 re-verified with no change.
- Study First Submitted
Endpoints
Primary
Percentage of Participants Achieving ACR50 Response
Timeframe: Week 12
Number of Participants Experiencing Adverse Events
Timeframe: Up to 80 Weeks
Secondary (7)
Percentage of Participants Achieving ACR20 Response
Percentage of Participants Achieving ACR70 Response
Percentage of Participants Achieving Low Disease Activity Based on DAS28 (CRP) <= 3.2
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) < 2.6
Percentage of Participants with a Change From Baseline in DAS28 (CRP)
Show 2 moreShow less
Percentage of Participants Achieving Low Disease Activity Based on Clinical Disease Activity Index (CDAI) <= 10
Percentage of Participants Achieving Clinical Remission Based on CDAI <= 2.8
Arms and interventions
ABBV-2294 Dose AExperimental
Participants will receive co-administration of ABBV-722 and upadacitinib
ABBV-2294 Dose BExperimental
Participants will receive co-administration of ABBV-722 and upadacitinib
ABBV-2294 Dose CExperimental
Participants will receive co-administration of ABBV-722 and upadacitinib
ABBV-722 MonotherapyExperimental
Participants will receive ABBV-722. At Week 12, participants will then be blindly switched to co-administration of ABBV-722 and upadacitinib.
Upadacitinib MonotherapyActive comparator
Participants will receive upadacitinib.
Drugs: ABBV-722, Upadacitinib